A phase II trial led by University of Michigan researchers found that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
John M. Ashton, associate professor in the department of biomedical genetics, has been promoted from assistant director to associate director of shared resources at the University of Rochester’s Wilmot Cancer Institute.
